779 - Capecitabine vs Cisplatin along with concurrent radiotherapy in the treatment of inoperable lower esophageal cancers focusing on TWISTT score and QOL

Background

The prognosis of patients with inoperable lower esophageal cancers remains poor with only option being concurrent chemo-radiation. Among the various agents available, there is no study done focusing on TWISTT score and QOL in southern Indian population.

Methods

This is a single-centre, two arm, retrospective analysis evaluating 75 patients with histologically confirmed inoperable adenocarcinoma esophagus lower 1/3^rd who are on definitive chemoradiation. The patients were administered IV cisplatin 40 mg/m² weekly IV (n = 38) as per institutional protocol vs Capecitabine 800 mg/m2 PO (n = 37) twice a day along with radiotherapy of 6600-7000 cGy over 35 fractions. Patients were evaluated over response evaluation criteria in solid tumors (RECIST) criteria 12 weeks after the last cycle of chemotherapy as well as for TWISTT score and QOL.

Results

The median duration of follow up was 20 months. Objective Response Rate (ORR) was observed in 84.2% of the patients with patients in the Cisplatin arm vs 86.4% in Capecitabine arm. There are no differences in the complete response (CR) and partial response (PR) rates in the two arms. The median overall survival was 20.7 months (95% CI: 18.8-, 28.7) in cisplatin arm vs 22.7 months (95% CI: 20.2-, 30.2). The median TWISTT score in Cisplatin was 246 days vs 228 days for capecitabine. The median QOL was similar in both arms.

Conclusions

Capecitabine vs Cisplatin along with concurrent radiotherapy had similar overall response rates and progression free survival with similar TWISTT score and QOL and either can be used for concurrent therapy based on physician/ patient preferences.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

A. Goutham.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.